AM 580Alternative Names: AGN-190293; AM-580
Latest Information Update: 17 Nov 2003
At a glance
- Originator W.R. Grace
- Developer Mitsubishi Pharma Corporation; Sumitomo Pharmaceuticals
- Class Antineoplastics; Benzoic acids; Retinoids; Small molecules
- Mechanism of Action Immunostimulants; Protein synthesis inhibitors; Retinoic acid receptor alpha agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Rheumatoid arthritis